1. HRAS germline mutations impair LKB1/AMPK signaling and mitochondrial homeostasis in Costello syndrome models
- Author
-
Dard, Laetitia, Hubert, Christophe, Esteves, Pauline, Blanchard, Wendy, About, Ghina Bou, Baldasseroni, Lyla, Dumon, Elodie, Angelini, Chloe, Delourme, Megane, Guyonnet-Duperat, Veronique, Claverol, Stephane, Fontenille, Laura, Kissa, Karima, Seguela, Pierre-Emmanuel, Thambo, Jean-Benoit, Nicolas, Levy, Herault, Yann, Bellance, Nadege, Amoedo, Nivea Dias, Magdinier, Frederique, Sorg, Tania, Lacombe, Didier, and Rossignol, Rodrigue
- Subjects
Gene mutations -- Research ,Medical research ,Medicine, Experimental ,Costello syndrome -- Development and progression ,Homeostasis -- Genetic aspects -- Health aspects ,Mitochondria -- Health aspects -- Genetic aspects ,Protein kinases -- Genetic aspects -- Health aspects ,Cellular signal transduction -- Research ,Health care industry - Abstract
Germline mutations that activate genes in the canonical RAS/MAPK signaling pathway are responsible for rare human developmental disorders known as RASopathies. Here, we analyzed the molecular determinants of Costello syndrome (CS) using a mouse model expressing HRAS p.G12S, patient skin fibroblasts, hiPSC-derived human cardiomyocytes, a HRAS p.G12V zebrafish model, and human fibroblasts expressing lentiviral constructs carrying HRAS p.G12S or HRAS p.G12A mutations. The findings revealed alteration of mitochondrial proteostasis and defective oxidative phosphorylation in the heart and skeletal muscle of CS mice that were also found in the cell models of the disease. The underpinning mechanisms involved the inhibition of the AMPK signaling pathway by mutant forms of HRAS, leading to alteration of mitochondrial proteostasis and bioenergetics. Pharmacological activation of mitochondrial bioenergetics and quality control restored organelle function in HRAS p.G12A and p.G12S cell models, reduced left ventricle hypertrophy in CS mice, and diminished the occurrence of developmental defects in the CS zebrafish model. Collectively, these findings highlight the importance of mitochondrial proteostasis and bioenergetics in the pathophysiology of RASopathies and suggest that patients with CS may benefit from treatment with mitochondrial modulators., Introduction Germline mutations that activate RAS/MAPK signaling are responsible for the 'RASopathies,' a group of rare human developmental diseases that affect more than 400,000 individuals in the United States alone. [...]
- Published
- 2022
- Full Text
- View/download PDF